New Hungary Pharma Report 2020 Out Now
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Address: Csorsz ut 49-51 H-1124 Budapest,Hungary
Tel: +36 1 577 8200
Web: http://www.astellas.com/worldwide.html
Astellas Pharma Europe the world’s 20 largest pharmaceutical company, belonging to 15 thousand employees worldwide Astellas Pharma Inc. subsidiary. As a young and forward-looking company Astellas aims to improve the quality of life for people around the world, innovative and reliable pharmaceutical products, by providing products.
In 2005, Yamanouchi and Fujisawa merger created Astellas remains committed to the class of the first (‘first-in-class’), and class best (‘best-in-class’) products developed for the key therapeutic areas by combining high R & D and marketing opportunities in the pharmaceutical world market continued growth.
In October 2006, Astellas has launched a company called Vision 2015 management strategy. Declared goal is to világelsőkké within that category (GAL) to become a number of therapeutic areas where further innovation of the patients currently unmet needs can be met. The company’s vision is an integral part in 2008, launched a wide-ranging Changing TOMORROW ™ (‘Change your tomorrow’) campaign, which displays the company’s ability to create a brighter future stakeholders, especially patients.
Significant, ongoing investments in research and development will further strengthen research-based Astellas pharmaceutical company capacity by providing effective medicines for patients worldwide, and continues to doctors and trusted partner of network deployment.
In Europe the main strengths of the Astella organ transplantation, urology, dermatology and anti-infective agents and the therapeutic areas of pain prevail. In addition, Astellas aims to develop a gyógyszerportfóliót the needs of cancer patients.
Astellas Pharma Europe Ltd. is based in Staines near London, and operates sales subsidiaries throughout Europe and the CIS states and South Africa. Astellas Pharma International, as well as licensors and distributors, the company responsible for the Middle East and Africa sales as well.
Geninax® : an oral new-type quinolone antibacterial agent
Celecox® : the selective COX-2 lnhibitor
Lipitor® : a treatment for hypercholesterolemia
Micardis® : a treatment for hypertension
Gaster® : a treatment for peptic ulcers and gastritis
Luvox® : an antidepressant
Myslee® : a hypnotic
Cefzon® : an oral cephalosporin
Seroquel® : an antipsychotic agent
Dorner® : a treatment for chronic arterial occlusion
Nasea® : a 5-HT3 (receptor) antagonist
Targocid® : a glycopeptide antibiotic
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
